4//SEC Filing
Kathiresan Sekar 4
Accession 0000950170-25-003854
CIK 0001840574other
Filed
Jan 9, 7:00 PM ET
Accepted
Jan 10, 9:00 AM ET
Size
10.1 KB
Accession
0000950170-25-003854
Insider Transaction Report
Form 4
Kathiresan Sekar
DirectorChief Executive Officer
Transactions
- Award
Stock Option (right to buy)
2025-01-08+488,000→ 488,000 totalExercise: $6.01Exp: 2035-01-07→ Common Stock (488,000 underlying) - Award
Restricted Stock Units
2025-01-08+120,000→ 120,000 total→ Common Stock (120,000 underlying) - Award
Stock Option (right to buy)
2025-01-08+150,000→ 150,000 totalExercise: $6.01Exp: 2035-01-07→ Common Stock (150,000 underlying)
Footnotes (4)
- [F1]The option was granted on January 8, 2025. 25% of the shares underlying the option will vest on January 8, 2026, and the remainder are scheduled to vest in equal monthly installments thereafter until January 8, 2029.
- [F2]Each restricted stock unit represents a contingent right to receive one share of common stock.
- [F3]On January 8, 2025, the reporting person was granted restricted stock units, vesting in three equal annual installments, beginning on April 1, 2026, and the remaining two installments vesting on April 1, 2027 and April 1, 2028.
- [F4]The option was granted on January 8, 2025. 100% of the shares underlying the option will vest immediately if and when the last quoted trading price per share of the Company's common stock on the Nasdaq Global Select Market is equal to or greater than $20.00 for at least 15 consecutive trading days on or prior to the second anniversary of the grant date.
Documents
Issuer
Verve Therapeutics, Inc.
CIK 0001840574
Entity typeother
Related Parties
1- filerCIK 0001864112
Filing Metadata
- Form type
- 4
- Filed
- Jan 9, 7:00 PM ET
- Accepted
- Jan 10, 9:00 AM ET
- Size
- 10.1 KB